Gain Therapeutics Announces Proposed Public Offering BETHESDA, Md.

Gain Therapeutics Announces

Proposed Public Offering

BETHESDA, Md., Nov. 20,

2023 - Gain Therapeutics, Inc. ("Gain" or the "Company") (Nasdaq: GANX) today announced that

it is proposing to offer and sell, subject to market conditions, shares of its common stock and warrants to purchase common stock

in an underwritten public offering. Gain expects to grant the underwriters a 30-day option to purchase up to an additional 15% of

the shares of common stock and/or the warrants offered in the offering. All of the shares of common stock and warrants are being offered

Gain intends to use the

net proceeds from the offering to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment

of neurodegenerative diseases including GBA1 Parkinson's disease and for general corporate purposes. The final terms of the offering

will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may

be completed, or as to the actual size or terms of the offering.

Newbridge Securities Corporation is acting as

the sole book-running manager for the proposed offering.

The securities described above will be offered

pursuant to a shelf registration statement on Form S-3 (File No. 333-265061), which was previously filed with the Securities

and Exchange Commission ("SEC") and became effective on June 1, 2022. A preliminary prospectus supplement and

accompanying base prospectus relating to and describing the terms of the offering and the concurrent private placement will be filed with

the SEC and will be available on the SEC's website located at www.sec.gov, copies of which may be obtained, when

available, for free by contacting Newbridge Securities Corporation, Attn: Equity Syndicate Department, 1200 North Federal Highway,

Suite 400, Boca Raton, FL 33432, by email at syndicate@newbridgesecurities.com or by telephone at (877) 447-9625.

The offering will be made only by means of a prospectus.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein,

nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be

unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc.

is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's

lead drug candidate GT-02287, in development for the treatment of GBA1 Parkinson's disease, is currently being evaluated in a Phase

Leveraging AI-supported

structural biology, proprietary algorithms and supercomputer-powered physics-based models, the company's SEE-Tx discovery platform

can identify novel allosteric binding sites on disease-implicated proteins, pinpointing pockets that cannot be found or drugged with current

technologies. Gain's unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt

protein function. Deploying its highly advanced platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments

for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.

Forward Looking Statement

This release contains

"forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of

1995. These statements are typically preceded by words such as "believes," "expects," "anticipates,"

"intends," "will," "may," "should," or similar expressions. These forward-looking statements

reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although

management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will

prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those

contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including,

but not limited to, risks associated with market conditions and the satisfaction of customary closing conditions related to the offering

and uncertainties related to the Company's expectations regarding the completion, timing and size of the proposed offering. For

a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking

statements, as well as risks relating to the Company's business in general, please refer to the Company's prospectus supplement

to be filed with the SEC, and the documents incorporated by reference therein, including the Company's Form 10-K for the year

ended December 31, 2022 and Forms 10-Q for the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023.

All forward-looking statements

are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking

statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update,

revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Investor & Media Contact:

Linnden Communications